Herantis Pharma | Wednesday, September 27th

Patient recruitment started and first patient consented in the CDNF Phase I-II clinical study

Read more
Herantis Pharma | Thursday, March 23rd

Herantis Pharma’s clinical study with CDNF in Parkinson’s disease authorized in Sweden

Read more
Herantis Pharma | Monday, December 12th

Herantis Pharma’s Parkinson study wins EUR 6.0 million grant from the European Union Horizon 2020 program

Read more